PARION SCIENCES, INC.

Basic Information

2525 MERIDIAN PKY, STE 260
DURHAM, NC, 27713-2261

Company Profile

n/a

Additional Details

Field Value
DUNS: 96851774
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Novel Mucolytic Agents

    Amount: $319,012.00

    DESCRIPTION (provided by applicant): Mucus transport is the fundamental defense of the airways against inhaled particulates/infectious agents. Abnormalities in the mucus transport system characterize ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Hypertonic Saline for Cystic Fibrosis

    Amount: $1,509,420.00

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, ...

    SBIR Phase II 2013 Department of Health and Human Services
  3. Hypertonic Saline for Cystic Fibrosis

    Amount: $244,797.00

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

    Amount: $1,059,726.00

    DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial dis ...

    SBIR Phase II 2011 Department of Health and Human Services
  5. The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

    Amount: $159,264.00

    DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial dis ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. PHARMACOTHERAPRY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

    Amount: $379,296.00

    DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disease characterized by lymphocyte- mediated destruction of exocrine glands and internal organ involv ...

    SBIR Phase II 2009 Department of Health and Human Services
  7. DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

    Amount: $983,544.00

    DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary c ...

    SBIR Phase II 2006 Department of Health and Human Services
  8. PHARMACOTHERAPY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

    Amount: $489,999.00

    DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disorder characterized by lymphocyte-mediated destruction ofOverall, this application was found to hav ...

    SBIR Phase I 2005 Department of Health and Human Services
  9. DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

    Amount: $364,501.00

    DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary c ...

    SBIR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government